CA2903254C - Liposomal cisplatin compositions for cancer therapy - Google Patents

Liposomal cisplatin compositions for cancer therapy Download PDF

Info

Publication number
CA2903254C
CA2903254C CA2903254A CA2903254A CA2903254C CA 2903254 C CA2903254 C CA 2903254C CA 2903254 A CA2903254 A CA 2903254A CA 2903254 A CA2903254 A CA 2903254A CA 2903254 C CA2903254 C CA 2903254C
Authority
CA
Canada
Prior art keywords
mol
cisplatin
composition
lipid
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2903254A
Other languages
English (en)
French (fr)
Other versions
CA2903254A1 (en
Inventor
William Mcghee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt LLC
Original Assignee
Mallinckrodt LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt LLC filed Critical Mallinckrodt LLC
Publication of CA2903254A1 publication Critical patent/CA2903254A1/en
Application granted granted Critical
Publication of CA2903254C publication Critical patent/CA2903254C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CA2903254A 2013-03-13 2014-03-13 Liposomal cisplatin compositions for cancer therapy Expired - Fee Related CA2903254C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780272P 2013-03-13 2013-03-13
US61/780,272 2013-03-13
PCT/US2014/026341 WO2014160337A1 (en) 2013-03-13 2014-03-13 Liposomal cisplatin compositions for cancer therapy

Publications (2)

Publication Number Publication Date
CA2903254A1 CA2903254A1 (en) 2014-10-02
CA2903254C true CA2903254C (en) 2019-04-09

Family

ID=50439522

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903254A Expired - Fee Related CA2903254C (en) 2013-03-13 2014-03-13 Liposomal cisplatin compositions for cancer therapy

Country Status (8)

Country Link
US (2) US10039716B2 (enExample)
EP (1) EP2968142A1 (enExample)
JP (1) JP6077710B2 (enExample)
CN (1) CN105209017A (enExample)
BR (1) BR112015022415A2 (enExample)
CA (1) CA2903254C (enExample)
MX (1) MX2015012199A (enExample)
WO (1) WO2014160337A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5994049B2 (ja) * 2012-10-01 2016-09-21 兵神装備株式会社 吐出システム
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
CA2977397A1 (en) * 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
PH12022550592A1 (en) * 2016-01-07 2023-07-17 Tesorx Pharma Llc Formulations for treating bladder cancer
WO2017142876A1 (en) 2016-02-15 2017-08-24 University Of Georgia Research Foundation, Inc. lPA-3-LOADED LIPOSOMES AND METHODS OF USE THEREOF
KR102483033B1 (ko) * 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
CA3050686A1 (en) * 2017-01-18 2018-07-26 Temasek Life Sciences Laboratory Limited Hyperstabilized liposomes increase targeting of mitotic cells
EP3706801B1 (en) * 2017-11-08 2026-01-14 L.E.A.F Holdings Group LLC Platinum complexes and uses thereof
WO2021183588A1 (en) 2020-03-10 2021-09-16 Chung Yuan Christian University Liposome composition and preparation method thereof
TW202345843A (zh) * 2022-04-06 2023-12-01 財團法人國家衛生研究院 脂質奈米顆粒及脂質體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US20020009488A1 (en) * 1995-05-03 2002-01-24 Polymasc Pharmaceuticals Plc Tissue entrapment
ATE252372T1 (de) * 1996-08-23 2003-11-15 Sequus Pharm Inc Liposome enthaltend cisplatin
EA002630B1 (ru) 1997-02-05 2002-08-29 Фармация Энд Апджон Компани Способ получения липидных комплексов или липосом водонерастворимого диаминоциклогександикарбоксилата платины
DE60110057T2 (de) * 2000-01-28 2005-09-08 Alza Corp., Mountain View Liposomen enthaltend eine eingeschlossene verbindung in übersattigter lösung
AU2002225878A1 (en) * 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
DE60222580T2 (de) * 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1716870A1 (en) * 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
JP5364381B2 (ja) 2006-12-08 2013-12-11 片山化学工業株式会社 アンミン白金錯体を高濃度で内包するリポソームおよびその製造方法

Also Published As

Publication number Publication date
MX2015012199A (es) 2015-11-30
CA2903254A1 (en) 2014-10-02
US20180318219A1 (en) 2018-11-08
JP6077710B2 (ja) 2017-02-08
CN105209017A (zh) 2015-12-30
BR112015022415A2 (pt) 2017-07-18
WO2014160337A1 (en) 2014-10-02
US10383823B2 (en) 2019-08-20
US10039716B2 (en) 2018-08-07
US20140271821A1 (en) 2014-09-18
EP2968142A1 (en) 2016-01-20
JP2016513651A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
US10383823B2 (en) Liposomal cisplatin compositions for cancer therapy
CA2903234C (en) Liposome oxaliplatin compositions for cancer therapy
US10213385B2 (en) Combinational liposome compositions for cancer therapy
CA2903255C (en) Modified docetaxel liposome formulations
US20180344644A1 (en) Improved stability of liposome formulations and uses thereof
EP3811931B1 (en) Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor
US20160250177A1 (en) Modified docetaxel liposome formulations and uses thereof
US20230330025A1 (en) Particle Modifiers for Multi-Drug Loaded Nanoparticles
US20210290537A1 (en) Liposomal elinafide formulations and uses thereof
CN114259469A (zh) 一种能够逆转肿瘤相关免疫衰老的唾液酸协助递送药物组合物及其制备方法和应用
US20200079785A1 (en) Mitomycin c prodrug liposome formulations and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150831

MKLA Lapsed

Effective date: 20210913

MKLA Lapsed

Effective date: 20200313